About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
The Clinical Significance of HER2+ Breast Cancer and Opportunities for Improved Outcomes
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
I
HER2 Targeted Treatments in Lower BC Expression Ranges
By
Miami Cancer Institute Precision Oncology Symposium
FEATURING
Ian Krop
By
Miami Cancer Institute Precision Oncology Symposium
FEATURING
Ian Krop
188 views
July 2, 2024
0 Comments
Login to view comments.
Click here to Login
13:28
Stanford Medicine
ADCs in HR+ Advanced/Metastatic BC
Feat.
M. Dolezal
21:20
Dana-Farber Cancer Institute
Older Adults With Breast Cancer: Research Updates
Feat.
R. Freedman
23:07
Keck School of Medicine of USC
2024 Updates on the Future of ADCs in Breast Cancer
Feat.
C. Geyer
20:31
OncoAlert
HER2+ mBC: Year-in-Review Including DESTINY Breast-03 & HER2CLIM…
Feat.
S. Graff
05:02
Total Health
CNS Metastasis in Breast Cancer: Surgery & Radiation Considerati…
Feat.
C. Santa-Maria
12:54
Total Health
Antibody Drug Conjugates: Highlights in Breast Cancer
Feat.
K. Kalinsky
19:34
Keck School of Medicine of USC
Breast Cancer Oligometastases and Beyond
Feat.
S. Chmura
15:26
Dana-Farber Cancer Institute
Antibody Drug Conjugates Highlights - mBC Series
Feat.
H. Burstein
25:25
Alessia Pellerino
Treatment Strategies for Leptomeningeal Disease in HER2+ mBC: Addres…
29:40
Insights from 2023 SABCS
Year in Review: Metastatic Breast Cancer
Feat.
M. Mac Gregor
03:28
Total Health
62 y/o With HER2+ mBC Who Underwent 2L TDXd Therapy: Case Presentati…
Feat.
P. Sharma,
M. Telli,
K. Kalinsky
21:31
Insights from ESMO Breast 2024 Annual Meeting
ESMO Breast 2024 Summary: "Community Oncologists Highlights&quo…
Feat.
S. Tolaney,
H. Rugo
12:07
Sara Tolaney
ESMO 2024 Noteworthy Abstracts in Breast Cancer
Feat.
H. Rugo
13:05
V.K. Gadi
Key Updates and Insights on HER2+ Breast Cancer
19:30
Elisa Agostinetto
The Evolving Landscape of Treatment Options in HER2+ mBC
04:04
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Updated Survival Data in DESTINY-Breast03…
Feat.
E. Hamilton
10:31
Sarah Premji
Treatment Selection in 2L for HER2+ MBC: Updated Guidelines, Safety …
21:01
Insights from ESMO Breast 2024 Annual Meeting
ESMO Breast 2024 Panel Discussion: "Key Updates in Breast Cance…
Feat.
S. Tolaney,
H. Rugo
11:57
V.K. Gadi
Clinical Guidance on the Management and Monitoring of T-DXd-Related …
10:09
Insights from ESMO Breast 2024 Annual Meeting
ESMO Breast 2024 Insights: "Pooled Analysis of T-DXd Retreatmen…
Feat.
H. Rugo
12:13
UChicago Medicine
Trastuzumab Deruxtecan in HER2+ mBC
Feat.
H. Rugo
17:48
MSKCC 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis
Frontiers in Breast Cancer Brain Metastasis: ADC Effectiveness in th…
Feat.
S. Modi
20:19
MSKCC 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis
Chemoprevention in Brain Mets: Breast Cancer Perspective
Feat.
A. Zimmer
